Evidence map›Paper›PMID 31722745›Full record

ArticleArthritis research & therapy2019

Interleukin-1 receptor antagonist (IL-1Ra) is more effective in suppressing cytokine-induced catabolism in cartilage-synovium co-culture than in cartilage monoculture.

Shikhar Mehta, Sumayyah Akhtar, Ryan M Porter, Patrik Önnerfjord, Ambika G Bajpayee

Registry-linked trialOpen access · goldAbstract readComparative Study
In one paragraph

Article in Arthritis research & therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06415461 (A Phase 1, Open Label Dose-Ranging Study to Assess the Safety, Tolerability, Preliminary Efficacy, and Dose Effect of CFL001 Cord Blood Product in Patients With Symptomatic Sacroiliac Joint Syndrome), which is not on this map. Cited by 46 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 1 pooled it
7.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06415461 phase1active not recruitingnot on this mapstarted 2024, after this paper: background citation

A Phase 1, Open Label Dose-Ranging Study to Assess the Safety, Tolerability, Preliminary Efficacy, and Dose Effect of CFL001 Cord Blood Product in Patients With Symptomatic Sacroiliac Joint Syndrome

TypeinterventionalSponsorUniversity of FloridaRan2024 to 2028Enrolled9ConditionsSacroiliac, Backache, Pain, BackArmsPremierMaxCB®-Platinum (CFL001)
3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 1 synthesis or guideline pooled it, 79 citations in OpenAlex.

  1. Cartilage · 2021
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Navigating the Hurdles of Intra-Articular AAV Gene Therapy.International journal of molecular sciences · 2025
    Review
  7. Observational
  8. Article
  9. Article
  10. Pararamosis, a Neglected Tropical Disease Induced byInternational journal of molecular sciences · 2024
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Shikhar MehtaDepartment of Bioengineering, Northeastern University, 805 Columbus Avenue, Boston, MA, 02120, USA.
Sumayyah AkhtarDepartment of Biochemistry, Northeastern University, 805 Columbus Avenue, Boston, MA, 02120, USA.
Ryan M PorterDepartments of Internal Medicine and Orthopaedic Surgery, University of Arkansas for Medical Sciences, 4301 W. Markham, Little Rock, AR, 72205, USA.
Patrik ÖnnerfjordDepartment of Rheumatology, Lund University, BMC-C12 Klinikgatan 28, 222 42, Lund, Sweden.
Ambika G BajpayeeDepartment of Bioengineering, Northeastern University, 805 Columbus Avenue, Boston, MA, 02120, USA. a.bajpayee@neu.edu.
Northeastern University · USLund University · SEUniversity of Arkansas for Medical Sciences · US

Funding

Understanding the Negative Prognostic Impact of Intraosseous Focal Lesions in Multiple MyelomaP20GM125503 · NIGMS · UNIV OF ARKANSAS FOR MED SCIS · PI Sanja Novak · 2018 to 2026
$23.0M
NIGMS NIH HHS P20 GM125503U.S. Department of Defense W81XWH-17-1-0085Vetenskapsrådet 2014-3303
6 · The paper itself

Abstract

backgroundMost in vitro studies of potential osteoarthritis (OA) therapies have used cartilage monocultures, even though synovium is a key player in mediating joint inflammation and, thereby, cartilage degeneration. In the case of interleukin-1 (IL-1) inhibition using its receptor antagonist (IL-1Ra), like chondrocytes, synoviocytes also express IL-1 receptors that influence intra-articular IL-1 signaling and IL-1Ra efficacy. The short residence time of IL-1Ra after intra-articular injection requires the application of frequent dosing, which is clinically impractical and comes with increased risk of infection; these limitations motivate the development of effective drug delivery strategies that can maintain sustained intra-articular IL-1Ra concentrations with only a single injection. The goals of this study were to assess how the presence of synovium in IL-1-challenged cartilage-synovium co-culture impacts the time-dependent biological response of single and sustained doses of IL-1Ra, and to understand the mechanisms underlying any co-culture effects.

methodsBovine cartilage explants with or without synovium were treated with IL-1α followed by single or multiple doses of IL-1Ra. Effects of IL-1Ra in rescuing IL-1α-induced catabolism in cartilage monoculture and cartilage-synovium co-culture were assessed by measuring loss of glycosaminoglycans (GAGs) and collagen using DMMB (dimethyl-methylene blue) and hydroxyproline assays, respectively, nitric oxide (NO) release using Griess assay, cell viability by fluorescence staining, metabolic activity using Alamar blue, and proteoglycan biosynthesis by radiolabel incorporation. Day 2 conditioned media from mono and co-cultures were analyzed by mass spectrometry and cytokine array to identify proteins unique to co-culture that contribute to biological crosstalk.

resultsA single dose of IL-1Ra was ineffective, and a sustained dose was necessary to significantly suppress IL-1α-induced catabolism as observed by enhanced suppression of GAG and collagen loss, NO synthesis, rescue of chondrocyte metabolism, viability, and GAG biosynthesis rates. The synovium exhibited a protective role as the effects of single-dose IL-1Ra were significantly enhanced in cartilage-synovium co-culture and were accompanied by release of anti-catabolic factors IL-4, carbonic anhydrase-3, and matrilin-3. A total of 26 unique proteins were identified in conditioned media from co-cultures, while expression levels of many additional proteins important to cartilage homeostasis were altered in co-culture compared to monocultures; principal component analysis revealed distinct clustering between co-culture and cartilage and synovium monocultures, thereby confirming significant crosstalk.

conclusionsIL-1Ra suppresses cytokine-induced catabolism in cartilage more effectively in the presence of synovium, which was associated with endogenous production of anti-catabolic factors. Biological crosstalk between cartilage and synovium is significant; thus, their co-cultures should better model the intra-articular actions of potential OA therapeutics. Additionally, chondroprotective effects of IL-1Ra require sustained drug levels, underscoring the need for developing drug delivery strategies to enhance its joint residence time following a single intra-articular injection.

Indexed as

AnimalsCartilageCattleCells, CulturedChondrocytesCoculture TechniquesCytokinesDose-Response Relationship, DrugHumansInterleukin-1alphaInterleukin 1 Receptor Antagonist ProteinMetabolismSynovial MembraneCytokinesIL1A protein, humanInterleukin-1alphaInterleukin 1 Receptor Antagonist ProteinCartilage-synovium co-cultureCrosstalkIL-1IL-1RaNitric oxideSustained dose

Identifiers

PMID31722745
PMCPMC6854651
OpenAlexW2986785016

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.